Primary prevention of rheumatoid arthritis

Completed

• Conditions: Rheumatoid arthritis; Musculoskeletal Diseases

• Registration Number: ISRCTN73232918
• Lead Sponsor: Jan van Breemen Instituut (Netherlands)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2005-12-20
• Last Update Posted: 13 January 2015

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

1. Age 18 - 70 years for RF+, 18+ for aCCP
2. Twice increased Immunoglobulin M (IgM)-RF and/or aCCP with 4+ weeks interval
3. Human Leukocyte Antigen (HLA)-DR Shared Epitope (SE) positive

Exclusion Criteria

Situations with possible false positive RF:
1. Auto-immune diseases
2. Active infection with hepatitis C or Ebstein Barr virus
3. Recent chemotherapy
4. Co-morbidity with decreased life expectancy
5. Corticosteroid use for another disease
6. Contra-indications for corticosteroids: diabetes mellitus, osteoporosis
7. Pregnancy or lactation

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
50% reduction of the concentration of the increased antibodies after 6 months compared to no treatment.

Secondary Outcome Measures

Name	Time	Method
Frequency of rheumatoid arthritis after 5 years compared to no treatment.